Visualization of genomic sequence in BRCA1 and BRCA2

Year : 2025 | Volume : 15 | Issue : 01 | Page : 49 55
    By

    Mandeep Kaur,

  • Amit Chawla,

  • Bharti,

  • Payal Rani,

  • Mangilal,

  • Vikramjit singh,

  • Sachin Poonia,

  • Mohit,

  • Lovepreet,

  1. Associate Professor, Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar,, Punjab, India
  2. Professor-Principal, Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar,, Punjab, India
  3. Research scholar, Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar, Punjab, India
  4. Associate Professor, Seth GL Bihani SD college of Tech. Edu. Sriganganagar, Rajasthan, India
  5. Assistant Professor, Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar, Punjab, India
  6. Research scholar, Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar, Punjab, India
  7. Assistant Professor, Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar, Punjab, India
  8. Assistant Professor, Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar, Punjab, India
  9. Research scholar, Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar, Punjab, India

Abstract

Heredity is the main reason of breast cancer in women and mutation or genetic variations also another reason for the spread of breast cancer. Heredity and genetic variations are responsible 5%-10%, 30%-50% respectively. There are 90% chances of developing neoplasm by the mutations. The effect of BRCA1 and BRCA2 may leads to the variations in DNA therefore it should be in limited amounts so that there will be minimum changes in DNA. The BRCA1 and BRCA2 helps to repair or heal the DNA sequences but it grows rapidly and causes cancer. BRCA1 and BRCA2 can carry out for the patients who have the past occurrence (family history) of the carcinoma. The past history is done by the clinical evidence or diagnosis of the particular patient.For the diagnosis, we can use the various methods blood test, mammogram, breast ultrasound, biopsy etc.The ayurvedic and allopathic treatment is useful for the cure of various kinds of cancers, the ayurvedic medicines such as herbal drugs are helpful because they have the anti-cancer properties as well as the allopathic treatment is also required because the tumour is suppress by these and the examples of pharmacological treatment like alkylating agents, plant producers, etc. BRCA1 and BRCA2 are cancer suppressor genes, the sequence of these coding regions shows no similarity to the proteins with each other. If one copy in the gene is mutated, the result becomes hereditary and transfer breast and ovarian cancer fronm one generation to other generation.

Keywords: BRCA1, BRCA2, DNA, Gene mutations, Alkylating agents.

[This article belongs to Research and Reviews: A Journal of Pharmacology ]

How to cite this article:
Mandeep Kaur, Amit Chawla, Bharti, Payal Rani, Mangilal, Vikramjit singh, Sachin Poonia, Mohit, Lovepreet. Visualization of genomic sequence in BRCA1 and BRCA2. Research and Reviews: A Journal of Pharmacology. 2025; 15(01):49-55.
How to cite this URL:
Mandeep Kaur, Amit Chawla, Bharti, Payal Rani, Mangilal, Vikramjit singh, Sachin Poonia, Mohit, Lovepreet. Visualization of genomic sequence in BRCA1 and BRCA2. Research and Reviews: A Journal of Pharmacology. 2025; 15(01):49-55. Available from: https://journals.stmjournals.com/rrjop/article=2025/view=201967


References

  1. Agarwal G, Ramakant P. Breast cancer care in India: the current scenario and the challenges for the future. Breast care. 2008 Feb 22;3(1):21-7 https://doi.org/10.1159/000115288 .
  2. Antoniou A, Pharoah PD, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30.
  3. Chang J, Chang, J., Elledge, R.M. Clinical management of women with genomic BRCA1 and BRCA2 mutations*. Breast Cancer Res Treat 69, 101–113 (2001). https://doi.org/10.1023/A:1012203917104
  4. Elizabeth B. Claus, Joellen Schildkraut, Edwin S. Iversen, Donald Berry, Giovanni Parmigiani, Effect of BRCA1 and BRCA2 on the Association Between Breast Cancer Risk and Family History, JNCI: Journal of the National Cancer Institute, Volume 90, Issue 23, 2 December 1998, Pages 1824–1829, https://doi.org/10.1093/jnci/90.23.1824
  5. Eeles, R.A. Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2, 283 (2000). https://doi.org/10.1186/bcr70
  6. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The American Journal of Human Genetics. 1998 Mar 1;62(3):676-89.
  7. Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S, Beckman KB, Pérez-Stable EJ, González Burchard E, Ziv E, Torres-Mejía G. European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1074-82. doi: 10.1158/1055-9965.EPI-09-1193.
  8. American Cancer Society. Survival rates for breast cancer. Last revised November 8, 2021.https://www.cancer.org/content/dam/CRC/PDF/Public/8580.00.pdf
  9. Sung JS. High-quality breast ultrasonography. Radiologic Clinics. 2014 May 1;52(3):519-26 https://www.radiologic.theclinics.com/article/S0033-8389(14)00029-3/abstract .
  10. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999; 354:1846–50 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)04336-6/fulltext
  11. Jaradat NA, Shawahna R, Eid AM, Al-Ramahi R, Asma MK, Zaid AN. Herbal remedies use by breast cancer patients in the West Bank of Palestine. Journal of Ethnopharmacology. 2016 Feb 3;178: 1-8 https://doi.org/10.1016/j.jep.2015.11.050 .
  12. Komen S. Resources AMERICAN CANCER SOCIETY Know what is normal for you. Available from: https://www.komen.org/wp-content/uploads/Screening-and-Early-Detection-Tri-Fold-9-15-FINAL.pdf
  13. Mahon Mac Brian “Epidemiology and the causes of breast cancer” Boston, MA, USA Int. J. Cancer: 118, 2373–2378 2006 https://doi.org/10.1002/ijc.21404 .
  14. Narod, S., Foulkes, W. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4, 665–676 (2004). https://doi.org/10.1038/nrc1431
  15. Neuhausen, S., Gilewski, T., Norton, L. et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 13, 126–128 (1996). https://doi.org/10.1038/ng0596-126
  16. Peter J. O’Donovan, David M. Livingston, BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair, Carcinogenesis, Volume 31, Issue 6, June 2010, Pages 961–967, https://doi.org/10.1093/carcin/bgq069 .
  17. Laure Perrin-Vidoz, Olga M. Sinilnikova, Dominique Stoppa-Lyonnet, Gilbert M. Lenoir, Sylvie Mazoyer, The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons, Human Molecular Genetics, Volume 11, Issue 23, 1 November 2002, Pages 2805–2814, https://doi.org/10.1093/hmg/11.23.2805 .
  18. Pike, M., Krailo, M., Henderson, B. et al. ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature 303, 767–770 (1983). https://doi.org/10.1038/303767a0
  19. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annual review of genetics. 1998 Dec;32(1):95-121 https://doi.org/10.1146/annurev.genet.32.1.95 .
  20. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. 2010. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol28: 893–901.
  21. SIMINOFF L. A. and FETTING H. J. L. “The Johns Hopkins Oncology Center, Baltimore, MD 21218, U.S.A.” Printed in Great Britain, Sot. Sci. Med. Vol. 32, No. 7, pp. 813-818, 1991
  22. Struewing, J., Abeliovich, D., Peretz, T. et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11, 198–200 (1995). https://doi.org/10.1038/ng1095-198
  23. Clemons AN. Susan G. Komen for the cure and the planned parenthood federation of America: A framework for non-profits beginning and ending a relationship with another organization (Doctoral dissertation) http://hdl.handle.net/2152/32180 .
  24. Tesoriero A, Andersen C, Southey M, et al. De novoBRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet1999; 65: 567–9.
  25. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. 2010. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol7:708–717.
  26. Tsongalis GJ, Linfert DR, Johnson RC, et al. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Arch Pathol Lab Med1998; 122: 548–50.
  27. Walode G. sanjay, s. chandan edition 3rd “a text book of medicinal chemistry-II” published by niraliprakashan 2.5 to 2.16.
  28. Breast cancer – Diagnosis and treatment – Mayo Clinic [Internet]. Mayoclinic.org. ; 2024 [cited 2025 Feb 1]. Available from: https://www.mayoclinic.org/diseases-conditions/breast-cancer/diagnosis-treatment/drc-20352475 ‌
Regular Issue Subscription Review Article
Volume 15
Issue 01
Received 17/01/2025
Accepted 04/02/2025
Published 25/02/2025
Publication Time 39 Days
144


My IP

PlumX Metrics